Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT05169333

The Oxford Risk Factors And Non-Invasive Imaging Study

The Oxford Risk Factors And Non-Invasive Imaging Study — Recruiting • Cardiology / Cardiovascular • NCT05169333.

📅 31 Jul 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT05169333
Sponsor
University of Oxford
Start
2016-02-23
ClinicaliQ Trial Snapshot
  • The Oxford Risk Factors And Non-Invasive Imaging Study — Recruiting • Cardiology / Cardiovascular • NCT05169333.
  • What is being tested: ORFAN is developing and validating novel biomarkers for cardiometabolic disease risk by combining CT imaging data with biological material collection in a diverse patient cohort across multiple UK centres.
  • Patient eligibility overview: This prospective observational study recruits a multi-ethnic cohort of participants to ensure biomarker findings are generalisable across different populations and risk profiles.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

ORFAN is a prospective, multi-centre, multi-ethnic cohort observational study collecting CT scans, biological material and outcomes data, to develop and validate novel biomarkers of cardiometabolic and other disease risk.

Eligibility Snapshot
  • : Inclusion Criteria for study Arms 1, 2 and 3: * Participant is willing and able to give informed consent for participation in the study. * Male or Female, aged 18 -99 years. Inclusion Criteria for study Arm 4: • Male or Female, aged 18 -99 years.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →
Guideline
Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment
Cardiology / Cardiovascular · 19 May 2026
AI-assisted echocardiography can support faster preliminary analysis and reporting of echo images in heart failure patients, potentially reducing reporting delays and improving…
View guideline →
Clinical Brief
Meet the teenagers calling for action on violence against women and girls
Cardiology / Cardiovascular · BBC Health · 28 Jul 2026
Teenage activists are mobilising public engagement on violence against women and girls (VAWG), highlighting widespread concern among younger generations about this health…
View brief →
Guideline
2024 ESC Guidelines for the Management of Atrial Fibrillation
Cardiology / Cardiovascular · 30 Mar 2026
Covers AF classification, stroke risk assessment (CHA2DS2-VASc), and bleeding risk (HAS-BLED) • Provides recommendations for rate vs rhythm control strategies • Addresses…
View guideline →
Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →
Guideline
2023 ESC Guidelines for the Management of Acute Coronary Syndromes
Cardiology / Cardiovascular · 30 Mar 2026
Covers rapid diagnosis and risk stratification for acute coronary syndromes (ACS) including STEMI and NSTEMI • Provides evidence-based recommendations for reperfusion strategies…
View guideline →